Sanofi and Transgene partnering on viral vectors; Russia's Rafarma strikes a new production deal;

> Sanofi ($SNY) and partner Transgene SA will invest €10 million to build a facility at the Genzyme Polyclonals site in Lyon, France to manufacture viral vectors for targeted cancer drugs. Report

> Two Russian drug companies, Rafarma Pharmaceuticals and St. Petersburg-based Pharmsynthez, are looking to create a production joint venture. Report

> CILS is now offering a computer printable label that will work on cyrovials, tubes and liquid straws stored down to -196ºC. Report

> India's Cadila says it has gotten FDA approval to market in the U.S. its Etodolac extended release tablets for the treatment of arthritis. Report

And Finally... Missouri late on Wednesday executed a man convicted of a killing when the U.S. Supreme Court denied his last-minute appeal that included questions about the purity of the pentobarbital to be used because it was made by a compounding pharmacy. Story